ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾

2023-07-12

ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©Á¢ÒìÒ©ÑÎËáÌæÄÉÅÁŵƬ?»ñÉÏÊÐÉêÇëÊÜÀí ÓÃÓÚÖÎÁÆÂýÐÔÉöÔಡѪ͸»¼Õ߸ßÁ×Ѫ֢

£¨2023Äê7ÔÂ12ÈÕ£¬£¬£¬£¬£¬ £¬ÖйúÉϺ££©7ÔÂ12ÈÕ£¬£¬£¬£¬£¬ £¬ÉϺ£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾£¨¡°ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¡±£¬£¬£¬£¬£¬ £¬¹ÉƱ´úÂ룺600196.SH£»£»£» £»£»£»£»£»02196.HK£©Ðû²¼£¬£¬£¬£¬£¬ £¬¿Ø¹É×Ó¹«Ë¾ÉϺ£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¹¤ÒµÉú³¤ÓÐÏÞ¹«Ë¾£¨¡°ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¹¤Òµ¡±£©»ñÔÊÐíÁ¢ÒìÒ©TenapanorƬ£¨ÑÎËáÌæÄÉÅÁŵƬ£¬£¬£¬£¬£¬ £¬¡°¸ÃÐÂÒ©¡±£©ÓÃÓÚ¿ØÖÆÕýÔÚ½ÓÊÜѪҺ͸ÎöÖÎÁƵÄÂýÐÔÉöÔಡ£¡£¡£ ¡£¡£¨CKD£©³ÉÈË»¼ÕߵĸßÁ×Ѫ֢µÄÒ©Æ·×¢²áÉêÇëÓÚ¿ËÈÕ»ñ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨¡°¹ú¼ÒÒ©¼à¾Ö¡±£©ÉóÆÀÊÜÀí¡£¡£¡£ ¡£¡£

TenapanorƬÊÇÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©´ÓArdelyxÔÊÐíÒýÈëµÄÒ»¿îFirst-in-class¿Ú·þ³¦µÀÄÆ/Çâ½»Á÷Ìå3£¨NHE3£©ÒÖÖƼÁ£¬£¬£¬£¬£¬ £¬2017Äê12Ô£¬£¬£¬£¬£¬ £¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¹¤Òµ»ñµÃÁËTenapanorƬÔÚÖк£Äڵء¢Ïã¸Û¼°°ÄÃÅÌØÊâÐÐÕþÇøµÄ¶À¼ÒÁÙ´²¿ª·¢ºÍÉÌÒµ»¯µÈȨÁ¦¡£¡£¡£ ¡£¡£TenapanorƬΪ»¯Ñ§Ò©Æ·£¬£¬£¬£¬£¬ £¬¸ÃÐÂÒ©ÓÃÓÚ±ãÃØÐͳ¦Ò×¼¤×ÛºÏÖ¢ÖÎÁÆÒÑÓÚ2019Äê9Ô»ñÃÀ¹úFDA£¨¼´ÃÀ¹úʳÎïºÍÒ©Æ·¼àÊÓÖÎÀí¾Ö£©ÉÏÊÐÅú×¼£¬£¬£¬£¬£¬ £¬²¢ÒÑÓÚ2023Äê3ÔÂÔÚÖйúÏã¸ÛÌØÊâÐÐÕþÇøµÝ½»ÉÏÊÐÉêÇ룻£»£» £»£»£»£»£»×èÖ¹ÏÖÔÚ£¬£¬£¬£¬£¬ £¬¸Ã˳Ӧ֢ÓÚÖйú¾³ÄÚ£¨²»°üÀ¨¸Û°Ą̈µØÇø£©ÒÑÍê³ÉIÆÚÁÙ´²ÊÔÑé½×¶Î¡£¡£¡£ ¡£¡£TenapanorƬÓÃÓÚ³ÉÈËÂýÐÔÉöÔಡ£¡£¡£ ¡£¡£¨CKD£©Í¸Îö»¼ÕßµÄѪÇåÁ׿ØÖƵÄÉÏÊÐÉêÇëÕýÔÚ½ÓÊÜÃÀ¹úFDAµÄ×¢²áÉó²é¡£¡£¡£ ¡£¡£

TenapanorƬ¿ÉÒÔïÔÌ­³¦µÀÄÆÀë×ÓÎüÊÕ£¬£¬£¬£¬£¬ £¬ÔöÌí³¦Ç»ÄÚË®·Ö£¬£¬£¬£¬£¬ £¬Ôö½ø³¦µÀÈ䶯ºÍÕý³£ÅűãµÄƵÂÊ¡£¡£¡£ ¡£¡£¶àÏîÃÀ¹úºÍÈÕ±¾µÄ¢ò¡¢¢óÆÚÑо¿Åú×¢TenapanorƬ¿ÉÏÔÖø½µµÍѪҺ͸Îö»¼ÕßÉý¸ßµÄѪÁ×ˮƽ£¬£¬£¬£¬£¬ £¬ÔÚ³¤´ï52ÖܵÄÓÃÒ©ÊÔÑéÖÐÒ²ÏÔʾËüµÄÖÎÁÆ¿ÉÄÍÊÜÐÔ£¬£¬£¬£¬£¬ £¬ÔÚÖйúÖÕÄ©ÆÚÉöÔಡ£¡£¡£ ¡£¡£¨ESRD£©ÑªÍ¸°é¸ßÁ×Ѫ֢»¼ÕßÖпªÕ¹µÄTenapanorƬ¢óÆÚÑо¿Ð§¹ûÓëÒѽÒÏþÑо¿Ð§¹ûÒ»Ö£¬£¬£¬£¬£¬ £¬Î´·¢Ã÷еÄÇå¾²ÐÔÐźÅ1.2.3.¡£¡£¡£ ¡£¡£Ñо¿Ð§¹ûÖ§³ÖTenapanorƬÓÃÓÚÖйúESRDѪ͸°é¸ßÁ×Ѫ֢»¼ÕߵĽµÁ×ÖÎÁÆ¡£¡£¡£ ¡£¡£2023Äê6ÔÂ16ÈÕµÚ68½ìÈÕ±¾Í¸Îöҽѧ»áÄêÉÏ£¬£¬£¬£¬£¬ £¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¿ÚÍ·»ã±¨ÁËTenapanorƬÖйúIIIÆÚÑо¿Ð§¹û¡£¡£¡£ ¡£¡£

¡ª¡ª¡ª¡ª¡ª¡ª¡ª¡ª

²Î¿¼ÎÄÏ×£º
1.Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. J Am Soc Nephrol 2019; 30: 641¨C52.
2.Inaba M, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial. Kidney Int Rep 2021; 7: 177¨C88.
3.Block GA, Bleyer AJ, Silva AL, et al. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). Kidney360 2021; 2: 1600¨C10.

¹ØÓÚÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©


ÉϺ£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾£¨¡°ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¡±£¬£¬£¬£¬£¬ £¬¹ÉƱ´úÂ룺600196.SH£¬£¬£¬£¬£¬ £¬02196.HK£©½¨ÉèÓÚ1994Ä꣬£¬£¬£¬£¬ £¬ÊÇÒ»¼ÒÖ²¸ùÖйú¡¢Á¢ÒìÇý¶¯µÄÈ«Çò»¯Ò½Ò©¿µ½¡¹¤Òµ¼¯ÍÅ£¬£¬£¬£¬£¬ £¬Ö±½ÓÔËÓªµÄÓªÒµ°üÀ¨ÖÆÒ©¡¢Ò½ÁÆÆ÷еÓëҽѧÕï¶Ï¡¢Ò½ÁÆ¿µ½¡Ð§ÀÍ£¬£¬£¬£¬£¬ £¬²¢Í¨¹ý²Î¹É¹úÒ©¿Ø¹ÉÁýÕÖµ½Ò½Ò©ÉÌÒµÁìÓò¡£¡£¡£ ¡£¡£


ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©ÒÔ»¼ÕßΪÖÐÐÄ¡¢ÁÙ´²ÐèÇóΪµ¼Ïò£¬£¬£¬£¬£¬ £¬Í¨¹ý×ÔÖ÷Ñз¢¡¢ÏàÖú¿ª·¢¡¢ÔÊÐíÒý½ø¡¢Éî¶È·õ»¯µÈ¶àÔª»¯¡¢¶àÌõÀíµÄÏàÖúģʽ£¬£¬£¬£¬£¬ £¬Ò»Á¬¸»ºñÁ¢Òì²úÆ·¹ÜÏߣ¬£¬£¬£¬£¬ £¬ÌáÉýFIC£¨First-in-class£¬£¬£¬£¬£¬ £¬¼´Í¬ÀàÊ×´´£©ÓëBIC£¨Best-in-class£¬£¬£¬£¬£¬ £¬¼´Í¬Àà×î¼Ñ£©ÐÂÒ©µÄÑо¿ÓëÁÙ´²¿ª·¢ÄÜÁ¦£¬£¬£¬£¬£¬ £¬¼ÓËÙÁ¢ÒìÊÖÒպͲúÆ·µÄÑз¢ºÍת»¯ÂäµØ¡£¡£¡£ ¡£¡£


ÔÚ¡°4IN¡±£¨Á¢ÒìInnovation¡¢¹ú¼Ê»¯ Internationalization¡¢ÖÇÄÜ»¯ Intelligentization¡¢ÕûºÏ Integration£©µÄÕ½ÂÔÖ¸µ¼Ï£¬£¬£¬£¬£¬ £¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©³Ð¼Ì¡°Á¢ÒìתÐÍ¡¢ÕûºÏÔËÓª¡¢ÎȽ¡ÔöÌí¡±µÄÉú³¤Ä£Ê½ÒÔ¼°Îª¹É¶«´´Á¢¼ÛÖµµÄÐÅÐÄ£¬£¬£¬£¬£¬ £¬Ò»Ö±ÔöÇ¿×ÔÖ÷Ñз¢ÓëÍⲿÏàÖú£¬£¬£¬£¬£¬ £¬¸»ºñ²úÆ·¹ÜÏߣ¬£¬£¬£¬£¬ £¬Ç¿»¯È«Çò»¯½á¹¹£¬£¬£¬£¬£¬ £¬ÌáÉýÔËӪЧÂÊ£¬£¬£¬£¬£¬ £¬Í¬Ê±£¬£¬£¬£¬£¬ £¬Æð¾¢ÍƽøÒ½ÁÆ¿µ½¡¹¤ÒµÏßÉÏÏßϽṹ£¬£¬£¬£¬£¬ £¬ÖÂÁ¦ÓÚ³ÉΪȫÇòÒ½ÁÆ¿µ½¡Êг¡µÄÒ»Á÷ÆóÒµ¡£¡£¡£ ¡£¡£


Ïàʶ¹«Ë¾¸ü¶à×ÊѶ¿ÉµÇ¼¹ÙÍø£ºwww.fosunpharma.com


Ç°Õ°ÐÔÉùÃ÷£º
±¾ÐÂΟå°üÀ¨Ç°Õ°ÐÔÉùÃ÷¡£¡£¡£ ¡£¡£³ý±¾ÐÂΟåËùÔصÄÀúÊ·ÊÂʵ³ÂÊöÍ⣬£¬£¬£¬£¬ £¬ËùÓаüÀ¨µ«²»ÏÞÓÚ±¾¹«Ë¾ÉÌÒµÕ½ÂÔµÄÌÖÂÛ£¬£¬£¬£¬£¬ £¬¹ØÓÚδÀ´ÔËÓª¡¢ÀûÈóÂÊ¡¢Ó¯ÀûÄÜÁ¦¡¢Á÷¶¯ÐÔºÍ×ÊÔ´×ÊÔ´¡¢±¾¹«Ë¾ÐÐҵδÀ´Éú³¤ºÍÖ÷ÒªÊг¡×ÜÌå¾­¼ÃδÀ´Éú³¤µÄÔ¤ÆÚµÄÌÖÂÛ£¬£¬£¬£¬£¬ £¬ÒÔ¼°ÈκÎÔÚ´Ë֮ǰ¡¢Ö®ºó»ò°üÀ¨ÖîÈç¡°ÆÚÍû¡±¡¢¡°×·Ç󡱡¢¡°ÐÅÍС±¡¢¡°ÍýÏ롱¡¢¡°ÍýÏ롱¡¢¡°Ô¤¼Æ¡±¡¢¡°ÏîÄ¿¡±¡¢¡°Ô¤ÆÚ¡±¡¢¡°¿ÉÄÜ¡±¼°¡°½«Òª¡±µÈÓ빫˾»òÆäÖÎÀí²ãÓйصÄÀàËÆ´ÊÓï»ò³ÂÊö£¬£¬£¬£¬£¬ £¬¾ùÖ¼ÔÚÈ·¶¨Ç°Õ°ÐÔ³ÂÊö¡£¡£¡£ ¡£¡£ÕâЩ³ÂÊöÊÜijЩÒÑÖªºÍδ֪µÄΣº¦¡¢²»È·¶¨ÐԺͼÙÉèµÄÓ°Ïì¿ÉÄܵ¼Ö¹«Ë¾µÄÏÖʵЧ¹û¡¢Òµ¼¨»ò³É¼¨ÓëÕâЩǰհÐÔÉùÃ÷Ëù±í´ï»òÌåÏÖµÄÈκÎδÀ´Ð§¹û¡¢Òµ¼¨»ò³É¼¨±£´æÖØ´ó²î±ð¡£¡£¡£ ¡£¡£Òò´Ë£¬£¬£¬£¬£¬ £¬Äú²»Ó¦Ì«¹ýÒÀÀµÈκÎÇ°Õ°ÐÔµÄ×ÊÁÏ¡£¡£¡£ ¡£¡£Æ¾Ö¤ÊÊÓõÄÖ´·¨¡¢¹æÔòºÍÌõÀýµÄÒªÇ󣬣¬£¬£¬£¬ £¬ÎÞÂÛÊÇÓÉÓÚеÄÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÉú³¤»òÆäËûÔµ¹ÊÔ­ÓÉ£¬£¬£¬£¬£¬ £¬±¾¹«Ë¾Ã»ÓÐÒ²²»¼ç¸ºÈκθüлòÒÔÆäËû·½·¨Ð޸ı¾ÐÂΟåÖеÄÇ°Õ°ÐÔÉùÃ÷µÄÒåÎñ¡£¡£¡£ ¡£¡£ÔÚ±¾ÐÂΟåÖУ¬£¬£¬£¬£¬ £¬Óйع«Ë¾ÒâÏòµÄÉùÃ÷»ò²Î¿¼ÎÄÏ××Ô±¾ÐÂΟåÐû²¼Ö®ÈÕÆðÉúЧ¡£¡£¡£ ¡£¡£ÈκδËÀàÒâͼ¶¼¿ÉÄÜËæ×ÅδÀ´µÄÉú³¤¶ø¸Ä±ä¡£¡£¡£ ¡£¡£±¾ÐÂΟåËùÔصÄËùÓÐÇ°Õ°ÐÔÉùÃ÷¾ù²ÎÕÕÉÏÊöÉêâÁÐÔÉùÃ÷¼ÓÒÔÏÞÖÆ¡£¡£¡£ ¡£¡£

ÉÏһƪ£ºÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©×ÔÑÐMEK1/2ÒÖÖƼÁFCN-159Ƭ»ñµÚ¶þÏîÍ»ÆÆÐÔÁÆ·¨È϶¨ ÏÂһƪ£ºÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©Á¢ÒìÐÍÈⶾËزúÆ·RT002ÖÎÁÆ˳Ӧ֢ÉÏÊÐÉêÇë»ñÊÜÀí
¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿